DGAP-Adhoc: Kardex AG: Kardex completes its strategic realignment
Kardex AG / Key word(s): Final Results 13.03.2014 06:00 Release of an ad hoc announcement pursuant to Art. 53 KR ...
mehr
Ergebnis der Suchanfrage nach Nü
Inhalte
- Sprache:
-
Medien:
Alle
- Zeitraum:
- Zeitraum:Gesamt
814 Treffer
Once-daily Epilepsy Treatment Zebinix® (Eslicarbazepine Acetate) Now Available with Full Reimbursement in Finland
Hatfield, England (ots/PRNewswire) - Eisai announces today that Zebinix(R) (eslicarbazepine acetate), a novel anti-epilepsy treatment, has received full reimbursement from the Finnish Health Authorities. Once-daily eslicarbazepine acetate, is indicated as adjunctive therapy in adults with partial onset seizures, ...
mehrNew First-in-class Epilepsy Treatment Fycompa® (perampanel) Launches in Spain
Hatfield, England (ots/PRNewswire) - Fycompa(R) (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), launches today in Spain. The new therapy is indicated for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 ...
mehrResverlogix Announces Combined RVX-208 Findings from SUSTAIN & ASSURE Phase 2b Trials
Calgary, Alberta (ots/PRNewswire) - "RVX-208 treated patients have significant lower MACE events in high risk CVD patients" TSX Exchange Symbol: RVX Resverlogix Corp. today announced new information arising from its ongoing analysis of data from both the SUSTAIN and ASSURE trials in atherosclerotic patients with high risk for recurrent events. This analysis, performed ...
mehrInfosys (NYSE: INFY) Announces Results for the Quarter Ended December 31, 2013
Mysore, India (ots/PRNewswire) - - Q3 revenues grew by 1.7% quarter-on-quarter; 9.9% year-on-year - Net profit grew by 20.9% quarter-on-quarter; 6.7% year-on-year Financial Highlights Consolidated results under International Financial Reporting Standards (IFRS) for the quarter ended December 31, 2013 - Revenues were $2,100 million for the quarter ended December 31, ...
mehrInnovative Metastatic Breast Cancer Treatment Halaven® (Eribulin) Recieves Reimbursement Approval in the Czech Republic
Hatfield, England (ots/PRNewswire) - Halaven(R) (eribulin) has received reimbursement approval in the Czech Republic as a highly innovative drug for patients with metastatic breast cancer, effective from the 1 January 2014. Eribulin is the first, single-agent chemotherapy to demonstrate a prolonged overall survival ...
mehr
Merck Serono Announces New Publication of Results of the Phase III START Trial Investigating Tecemotide in Non-Small Cell Lung Cancer in The Lancet Oncology
Darmstadt, Germany (ots/PRNewswire) - - Publication offers detailed results of START, including an exploratory analysis of the clinically meaningful survival prolongation with tecemotide maintenance therapy in a predefined subgroup of patients treated with concurrent chemoradiotherapy - As previously announced Merck ...
mehrFirst-In-Class Treatment Fycompa® (Perampanel) Launched in Finland for Most Common Form of Epilepsy
Hatfield, England (ots/PRNewswire) - Epilepsy treatment Fycompa(R)(perampanel) has today been approved for basic reimbursement in Finland. Perampanel is indicated as an adjunctive treatment for partial onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] Perampanel is the first and only licensed ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe
Paris, France (ots/PRNewswire) - Yervoy, an innovative immuno-oncology therapy that has demonstrated durable long-term survival in some patients,[1],[2] is now approved for use in previously-untreated patients Bristol-Myers Squibb today announced that the European Commission (EC) has approved YERVOY(R) (ipilimumab) ...
mehrPivotal Study of Investigational 9-Valent HPV Vaccine Demonstrates Additional Protection Against HPV-Related Disease
Lyon, France (ots/PRNewswire) - - New 9-valent HPV vaccine prevented 97% of cervical, vaginal and vulvar pre-cancers caused by five additional HPV types - Immunogenicity non-inferior to GARDASIL for original four HPV types Lyon, 4 November 2013 - Sanofi Pasteur MSD reported today that Merck's investigational ...
mehrDebiotech and AWAK enter into joint Agreement for the development and manufacturing of a novel miniaturized Home Hemodialysis machine
Lausanne and Singapore (ots) - Debiotech SA, Switzerland, and AWAK Technologies Pte Ltd., Singapore, announced today that they have entered into a partnership agreement regarding the development and manufacturing of a novel miniaturized Home Hemodialysis machine intended to serve the growing need for homecare ...
mehrCORRECTION - Bayer Healthcare: 500,000 People Call for Urgent Action to Prevent Atrial Fibrillation-Related Strokes
Berlin (ots/PRNewswire) - In the news release, "500,000 People Call for Urgent Action to Prevent Atrial Fibrillation-Related Strokes" issued on 29 Oct 2013 00:01 GMT, by Bayer Healthcare over PR Newswire, we are advised by a representative of the company that in paragraph five the words 'premature mortality from' ...
mehr
500,000 People Call for Urgent Action to Prevent Atrial Fibrillation-Related Strokes
Berlin (ots/PRNewswire) - Atrial fibrillation is an under-diagnosed, undertreated abnormal heart rhythm that increases stroke risk five-fold compared to the general population World Stroke Day 2013 By World Stroke Day 2013 (October 29) more than 500,000 people have shown their support for the Sign Against Stroke in Atrial Fibrillation campaign, calling for urgent ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy(TM) (Ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable Melanoma
Princeton, New Jersey (ots/PRNewswire) - - In this pooled analysis of 12 studies, a plateau in the survival curve begins at approximately three years, with some patients followed for up to ten years - Three-year estimated survival rate of 22% observed in patients treated with ipilimumab - Findings are based on ...
mehrSanofi announces upcoming launch of MyStar Extra®, the first self- monitoring blood glucose meter with estimated A1c
Paris (ots) - - CE marks obtained for MyStar Extra® and MyStar SylkFeel® lancing device, respectively, enabling commercialization in the European Union - Scientific data presented at EASD 2013 demonstrate robustness and accuracy[i],[ii] of estimated A1c algorithm in MyStar Extra® At the annual meeting of the ...
mehrConstellium Reports Second Quarter 2013 Financial Results
Amsterdam (ots/PRNewswire) - Constellium N.V. today reported the following results for the three months ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20130624/NY37453LOGO [http://photos.prnewswire.com/prnh/20130624/NY37453LOGO] ) Second Quarter Highlights: -- Adjusted EBITDA of EUR85 million - a new quarterly high -- Strong cash flow from higher EBITDA and continued focus on working capital management, ...
mehrData Reveals Changes in Management of Patients Living with Atrial Fibrillation in Europe
Ehra Europace 2013, Athens, Greece (ots/PRNewswire) - [For European Media Only, Not for UK Media] Baseline data from The PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF) highlights advances and existent gaps in current management of thromboembolic events in people with AF Daiichi Sankyo Europe GmbH today announced the first ...
mehr23rd European Meeting on Hypertension and Cardiovascular Protection
München (ots) - New data from the SEVITENSION study show the fixed-dose combination treatment Sevikar® (olmesartan/amlodipine) to be superior to perindopril in combination with amlodipine in reducing central blood pressure When the traditional arm (brachial) method of measurement is used, blood pressure is usually found to be higher than it is in the large central ...
mehr
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Paris (ots/PRNewswire) - - EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus(R)- - Topline results of EDITION II consistent with EDITION I findings - Sanofi announced today that the first phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with ...
mehrSanofi to Present New Clinical Data, Including Results From the Investigational New Insulin U300, at the American Diabetes Association 73rd Scientific Sessions
Paris (ots/PRNewswire) - Sanofi announced today that clinical data highlighting the company's ongoing commitment to advancing diabetes care will be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions in Chicago, USA (June 21-25, 2013). In total, more than 60 abstracts representing new data ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma
Princeton, New Jersey (ots/PRNewswire) - Intended only for European media based outside of the UK - 53% response rate observed in patients receiving 1 mg/kg nivolumab plus 3 mg/kg Yervoy concurrently (n= 9 of 17), the dose used in the Phase 3 trial; of these responders all experienced at least 80% tumor shrinkage ...
mehrJanssen Infectious Diseases-Diagnostics BVBA
INCIVO® (telaprevir) Receives European Commission Approval for Twice Daily Dosing for Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV)
Beerse, Belgium (ots/PRNewswire) - -INCIVO(R) triple therapy now offers a twice daily HCV treatment regimen which should improve patient adherence[1] - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) announced today that the European Commission (EC) has approved a new twice daily (BID) dosing of INCIVO(R) ...
mehrPBAC Approves XIFAXAN® (Rifaxamin a) 550 mg Cost Effectiveness in Australia
London (ots/PRNewswire) - Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition ...
mehrFirst Clinical Experiences With Fycompa® (perampanel) Show "Clear Therapeutic Benefit"
Hatfield, England (ots/PRNewswire) - New data on early real life experience show perampanel is effective and well tolerated in patients with difficult-to-treat partial epilepsy The antiepileptic drug (AED) Fycompa (perampanel), shows a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy according to the investigators of two new analyses on ...
mehr
Pivotal Therapeutics VASCAZEN®-REVEAL Trial Meets Primary and Secondary Endpoints - VASCAZEN® Shows 121% Correction of an Omega-3 Deficiency (p< 0.0001) with a Concomittant 48% Reduction in Triglycerides (p<0.0005)
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, presented positive, statistically significant, top-line results from its VASCAZEN(R)-REVEAL trial for ...
mehrINCIVO® Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for Twice Daily Dosing for Treatment of Genotype-1 Hepatitis C Virus
Beerse, Belgium (ots/PRNewswire) - - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA ...
mehrDaiichi Sankyo Company (TSE: 4568) and Perosphere Inc
Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban
Mount Kisco, New York And Tokyo (ots/PRNewswire) - Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and ...
mehrBristol-Myers Squibb GmbH & Co. KGaA
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection
Princeton, New Jersey (ots/PRNewswire) - - This all-oral treatment regimen is being studied as an interferon-free and ribavirin-free option - Investigational regimen involves three different classes of direct-acting antivirals (DAAs) - an NS5A replication complex inhibitor, an NS3 protease inhibitor and an NS5B ...
mehrResverlogix Completes Dosing in ASSURE Clinical Trial
Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low ...
mehrArticle Published in JAMA Dermatology Shows Long-term Effectiveness of Ingenol Mebutate in Treating Actinic Keratosis
Ballerup, Denmark (ots/PRNewswire) - Two-three day treatment provides clinically relevant, sustained clearance of AK after 12 months An analysis of long-term clearance rates of actinic keratosis (AK) lesions after treatment with ingenol mebutate (Picato(R)) gel is today published in the Journal of the American ...
mehr
Vorherige78910111213141516Nächste